Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of composition containing riluzole and borneol in preparation of medicine for treating cerebrovascular diseases

A composition and technology for cerebrovascular diseases, applied in the direction of medical preparations containing active ingredients, drug combinations, cardiovascular system diseases, etc., to achieve the effect of increasing drug efficacy

Pending Publication Date: 2022-08-02
NEURODAWN PHARM CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, a systematic review and meta-analysis of riluzole for the treatment of neurodegenerative motor diseases, including PD, atypical Parkinson's disease, Huntington disease (HD), hereditary ataxia, etc., concluded that, The effect of riluzole on symptoms in patients with hereditary ataxia appears promising, but further clinical validation studies are needed ( drug Delivery, 2017, 25(1), 43–48 )

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of composition containing riluzole and borneol in preparation of medicine for treating cerebrovascular diseases
  • Application of composition containing riluzole and borneol in preparation of medicine for treating cerebrovascular diseases
  • Application of composition containing riluzole and borneol in preparation of medicine for treating cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Effects of riluzole and d-camphenol NMDA-induced excitatory damage in primary cortical neurons

[0029] 1 Materials and methods

[0030] 1.1 Animals

[0031] SD pregnant rats, Shanghai Slack Laboratory Animal Co., Ltd. (production license number: SCXK (Shanghai) 2017-0005)

[0032] 1.2 Reagents and Consumables

[0033] name Article / Lot Number manufacturer Neurobasal 21103-049 Gibco B27 17504-044 Gibco GlutaMax 2110349 Gibco CellTiter-Glo G7571 Promega Polylysine (PDL) P6407 Sigma DMEM 11995-040 Gibco Sugar-free DMEM 1763966 Gibco Pennicillin Streptomycin (P / S) 15140-122 Gibco Fetal Bovine Serum (FBS) 10099-141 Gibco Cell Culture Plate Corning 3610 / 96 well cell culture plate Corning Riluzole R129533-5g (Lot1502089) Aladdin Dex-camphenol KC20171205-1-2 Jiangsu Ouwei Pharmaceutical Co., Ltd. Luminescent Cell Viability Assay LOT 7E322D9 Nanjing...

Embodiment 2

[0050] Example 2 The effect of riluzole and d-camphenol composition on NMDA-induced excitatory injury of primary cortical neurons

[0051] 1 Materials and methods

[0052] 1.1 Animals Same as Example 1

[0053] 1.2 Reagents and consumables are the same as in Example 1

[0054] 1.3 Preparation of primary cortical neurons Same as Example 1

[0055] 1.4 NMDA-induced excitatory injury test of primary cortical neurons

[0056] In vitro matured primary neuronal medium was replaced with Locke's buffer containing varying concentrations of riluzole (R), d-camphenol (B), or a combination of riluzole and d-camphenol (RB) (see Table 1). solution (NaCl 154mM, KCl 5.6mM, NaHCO 3 3.6mM, CaCl 2 2.3 mM, D-Glucose 5.6 mM, HEPES 5 mM, pH 7.4), after incubation at 37°C for 10 min, add excitability inducers (NMDA final concentration 100 µM and Glycine final concentration 10 µM) for 30 min; aspirate and discard the induction buffer containing 1 mM MgCl 2 After washing once with Locke’s buff...

Embodiment 3

[0066] Example 3 Synergistic study of riluzole and d-camphenol composition (20:1) in protecting primary neurons from excitatory injury

[0067] 1 Materials and methods

[0068] 1.1 Animals Same as Example 1

[0069] 1.2 Reagents and consumables are the same as in Example 1

[0070] 1.3 Preparation of primary cortical neurons Same as Example 1

[0071] 1.4 NMDA-induced excitatory injury test of primary cortical neurons

[0072] In vitro matured primary neuron culture medium was replaced with Locke's buffer ( See Table 2), after incubation at 37 °C for 10 min, add excitability inducers (final concentration of NMDA 100 µM and Glycine final concentration 10 µM) for 30 min; after aspirating and discarding the induction buffer, add 1 mM MgCl 2 After washing once with Locke’s buffer, change to completion medium (100 μL / well) to resume culturing for 4 h.

[0073] Table 2 The concentration design of riluzole dex-camphenol composition

[0074] Riluzole (µM) Dex Camphen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a composition applied to preparation of a medicine for treating cerebrovascular diseases, in particular to ischemic cerebrovascular diseases, and the composition contains 2-amino-6-trifluoromethoxy benzothiazole or pharmaceutically acceptable salts thereof and borneol.

Description

technical field [0001] The invention belongs to the field of pharmacy and relates to the application of a 2-amino-6-trifluoromethoxybenzothiazole and borneol or d-camphenol composition in preparing a medicine for treating cerebrovascular disease, especially ischemic cerebrovascular disease. Background technique [0002] Cerebrovascular disease (CVD) refers to brain lesions caused by various cerebrovascular diseases. According to its pathogenesis, it can be divided into acute cerebrovascular disease (stroke) and chronic cerebrovascular disease. Acute cerebrovascular disease includes transient ischemic attack, cerebral thrombosis, cerebral embolism, hypertensive encephalopathy, cerebral hemorrhage and subarachnoid hemorrhage; chronic cerebrovascular disease includes cerebral arteriosclerosis, cerebrovascular dementia, cerebral artery disease Steal syndrome, Parkinson's disease, etc. Ischemic stroke (Stroke) is a general term for brain tissue necrosis caused by stenosis or occ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/428A61K31/045A61P9/10
CPCA61K31/428A61K31/045A61P9/10A61K2300/00A61K9/0019
Inventor 张正平王磊陈荣
Owner NEURODAWN PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com